Soleno Therapeutics (SLNO) Operating Margin (2016 - 2017)
Historic Operating Margin for Soleno Therapeutics (SLNO) over the last 5 years, with Q2 2017 value amounting to 296800.0%.
- Soleno Therapeutics' Operating Margin fell 1820500000.0% to 296800.0% in Q2 2017 from the same period last year, while for Dec 2017 it was 4575.56%, marking a year-over-year decrease of 35999300.0%. This contributed to the annual value of 81242.86% for FY2024, which is N/A changed from last year.
- As of Q2 2017, Soleno Therapeutics' Operating Margin stood at 296800.0%, which was down 1820500000.0% from 518.11% recorded in Q1 2017.
- In the past 5 years, Soleno Therapeutics' Operating Margin registered a high of 195.07% during Q2 2014, and its lowest value of 296800.0% during Q2 2017.
- Moreover, its 5-year median value for Operating Margin was 645.95% (2016), whereas its average is 28691.43%.
- Per our database at Business Quant, Soleno Therapeutics' Operating Margin surged by 100735800bps in 2016 and then tumbled by -1820500000bps in 2017.
- Soleno Therapeutics' Operating Margin (Quarter) stood at 173.91% in 2013, then tumbled by -54bps to 79.54% in 2014, then crashed by -1926bps to 1452.24% in 2015, then skyrocketed by 56bps to 645.95% in 2016, then crashed by -45848bps to 296800.0% in 2017.
- Its last three reported values are 296800.0% in Q2 2017, 518.11% for Q1 2017, and 645.95% during Q4 2016.